AGP Executive Report
Last update: 9 hours agoFDA & Biotech: Takeda says the FDA accepted its priority-review NDA for zasocitinib (TAK-279), an oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis, aiming for rapid, durable skin clearance. Massachusetts Life Sciences: Gov. Maura Healey met biotech startups on financing needs as the state looks to bolster early-stage funding through the Mass. Life Sciences Center. Clinical Oncology: NANOBIOTIX reported complete Phase 1 cohort results for radiotherapy-activated JNJ-1900 (NBTXR3) in inoperable, recurrent NSCLC, with locoregional control and safety updates. AI Governance Debate: MIT and other schools are embedding DEI and “responsible” themes into AI programs, while national AI risk warnings and calls to slow development keep colliding with tech optimism. Energy & Industry: Hyundai backed Commonwealth Fusion Systems in a $1B raise, signaling more industrial muscle for Massachusetts fusion plans. Local Tech & Privacy: Massachusetts towns are rethinking Flock automated license plate reader cameras, with pilots ended or paused amid privacy and misuse concerns. STEM & Education: UVM expanded tuition discounts for New England students in select majors to boost enrollment and workforce pipelines. Health Tech: An AI tool is being highlighted for faster, more accurate prostate cancer dosing predictions.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
